Market Research Logo

Sri Lanka Pharmaceuticals & Healthcare Report Q2 2018

Sri Lanka Pharmaceuticals & Healthcare Report Q2 2018

BMI View:

Sri Lanka’s pharmaceutical and healthcare expenditure will continue to expand over the forecast period, driven byhealthcare system development and rising demand for chronic disease treatment. Despite rising consumption of brandedmedicines, growing volume sales of lower-cost drugs will continue to underpin market growth in the near term, given low per capitapharmaceutical expenditure. Meanwhile, the government incentive to localise pharmaceutical production will continue to graduallyreshape the competitive landscape in the country. Although we expect foreign investment to increase given the market's long-termdevelopment potential, the country's limited commercial rewards means multinational drugmakers will have little incentive to investand develop a large manufacturing presence in the country in the near term.


BMI Industry View
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Industry Risk/Reward Index
Asia Pacific Pharmaceuticals: Region Characterised By A Mix Of Risks And Rewards
Sri Lanka Risk/Reward Index
Regulatory Development
Regulatory Review
Industry Trends And Developments
Market Overview
Competitive Landscape
Company Profile
GlaxoSmithKline
Hemas Holdings
State Pharmaceuticals Corporation (SPC)
Demographic Forecast
Demographic Outlook
Pharmaceuticals & Healthcare Glossary
Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report